Renal Impairment Does Not Compromise Dabigatran Reversal by Idarucizumab

Key Points

• This study aims to determine if renal impairment affects the reversal of dabigatran by idarucizumab.
• Randomized trial evaluating the effect of idarucizumab on dabigatran reversal.
• Participants included individuals with varying degrees of renal impairment.
• Comparative analysis of reversal effectiveness across different renal function groups.
• Idarucizumab effectively reversed dabigatran anticoagulation regardless of renal impairment status.
• No significant differences in the pharmacokinetics of idarucizumab were observed.
• The safety profile of idarucizumab remained consistent across all renal function levels.